24.06
-0.87(-3.49%)
Currency In USD
| Previous Close | 24.93 |
| Open | 24.58 |
| Day High | 25.17 |
| Day Low | 23.74 |
| 52-Week High | 34.1 |
| 52-Week Low | 7.78 |
| Volume | 87,497 |
| Average Volume | 544,930 |
| Market Cap | 333.34M |
| PE | -16.48 |
| EPS | -1.46 |
| Moving Average 50 Days | 21.28 |
| Moving Average 200 Days | 12.96 |
| Change | -0.87 |
If you invested $1000 in Greenwich LifeSciences, Inc. (GLSI) since IPO date, it would be worth $4,812 as of February 21, 2026 at a share price of $24.06. Whereas If you bought $1000 worth of Greenwich LifeSciences, Inc. (GLSI) shares 5 years ago, it would be worth $681.01 as of February 21, 2026 at a share price of $24.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy
GlobeNewswire Inc.
Jan 27, 2026 11:00 AM GMT
STAFFORD, Texas, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designat
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
GlobeNewswire Inc.
Jan 22, 2026 11:00 AM GMT
STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immuno
Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026
GlobeNewswire Inc.
Dec 29, 2025 11:00 AM GMT
STAFFORD, Texas, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating Fast Track designat